J&J beats Tagris­so and Take­da to the punch in key NSCLC sub­set, pick­ing up new FDA ap­proval

Look­ing to out­flank As­traZeneca’s best-sell­ing drug in a non-small cell lung can­cer niche, J&J scored an im­por­tant ap­proval Fri­day af­ter­noon.

Reg­u­la­tors gave the thumbs-up to Janssen’s ami­van­tam­ab for the treat­ment of metasta­t­ic NSCLC with EGFR ex­on 20 in­ser­tion mu­ta­tions, the FDA an­nounced Fri­day. It’s the first drug ap­proved to treat such pa­tients, with J&J plant­i­ng a stake in a part of the EGFR mu­ta­tion are­na where its com­peti­tors have strug­gled to gain a foothold.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER